Stryker Co. (NYSE:SYK) Holdings Lessened by Ramsay Stattman Vela & Price Inc.

Ramsay Stattman Vela & Price Inc. reduced its stake in shares of Stryker Co. (NYSE:SYK) by 0.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,060 shares of the medical technology company’s stock after selling 191 shares during the quarter. Stryker comprises about 3.4% of Ramsay Stattman Vela & Price Inc.’s investment portfolio, making the stock its 6th biggest position. Ramsay Stattman Vela & Price Inc.’s holdings in Stryker were worth $18,024,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Stratos Wealth Advisors LLC boosted its stake in shares of Stryker by 3.4% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 4,177 shares of the medical technology company’s stock worth $1,509,000 after purchasing an additional 139 shares during the period. Capital Investment Advisors LLC boosted its position in shares of Stryker by 102.5% during the third quarter. Capital Investment Advisors LLC now owns 1,855 shares of the medical technology company’s stock valued at $670,000 after buying an additional 939 shares during the period. New Century Financial Group LLC grew its stake in shares of Stryker by 7.5% during the third quarter. New Century Financial Group LLC now owns 858 shares of the medical technology company’s stock valued at $310,000 after buying an additional 60 shares during the last quarter. Godsey & Gibb Inc. lifted its stake in shares of Stryker by 0.6% during the 3rd quarter. Godsey & Gibb Inc. now owns 67,260 shares of the medical technology company’s stock worth $24,298,000 after acquiring an additional 402 shares during the last quarter. Finally, Brown Lisle Cummings Inc. lifted its stake in shares of Stryker by 22.5% during the 3rd quarter. Brown Lisle Cummings Inc. now owns 6,386 shares of the medical technology company’s stock worth $2,307,000 after acquiring an additional 1,175 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Price Performance

Shares of SYK opened at $385.05 on Tuesday. The company has a 50 day moving average of $377.31 and a two-hundred day moving average of $367.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a market cap of $146.79 billion, a price-to-earnings ratio of 49.62, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business posted $3.46 earnings per share. As a group, analysts predict that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s payout ratio is currently 43.30%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on SYK. JPMorgan Chase & Co. increased their target price on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Truist Financial upped their target price on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research note on Thursday, January 30th. Evercore ISI increased their price objective on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, Robert W. Baird lifted their target price on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $420.68.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.